Director, Clinical Monitoring Oversight

(OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer..., OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through...

Lugar: Boston, MA | 25/12/2025 02:12:34 AM | Salario: S/. $235000 - 250000 per year | Empresa: Olema Oncology

Director, Clinical Monitoring Oversight

(OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer..., OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through...

Lugar: San Francisco, CA | 24/12/2025 22:12:54 PM | Salario: S/. $235000 - 250000 per year | Empresa: Olema Oncology

Director, GMP and Quality Systems Compliance

(OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer..., OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through...

Lugar: San Francisco, CA | 25/12/2025 02:12:02 AM | Salario: S/. $225000 - 240000 per year | Empresa: Olema Oncology

Director, GMP and Quality Systems Compliance

(OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer..., OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through...

Lugar: Boston, MA | 25/12/2025 02:12:33 AM | Salario: S/. $225000 - 240000 per year | Empresa: Olema Oncology

Head of Product Development

. Whatever your title, whatever your role — it always comes back to this: we’re a farmer-owned co-op where everyone rolls up their sleeves...

Lugar: Lakeville, MA | 30/10/2025 23:10:42 PM | Salario: S/. $160800 - 232760 per year | Empresa: Ocean Spray

Director, Analytical Development

(OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer..., OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through...

Lugar: Boston, MA | 20/12/2025 22:12:45 PM | Salario: S/. $215000 - 230000 per year | Empresa: Olema Oncology

Director, Analytical Development

(OP-1250), is a complete estrogen receptor antagonist (CERAN) currently in development for metastatic breast cancer..., OP-3136, is a potent KAT6 inhibitor with best-in-class potential. Our scientific breakthroughs are accelerated through...

Lugar: San Francisco, CA | 20/12/2025 21:12:30 PM | Salario: S/. $215000 - 230000 per year | Empresa: Olema Oncology
12345678910